Navinci Secures €5.3 Million in Funding from Existing Owners and a Strategic Investment from Jonathan Milner at Meltwind
Uppsala, Sweden – June 25, 2025 – Navinci, a Swedish life science tools company specializing in developing innovative solutions for studying proteins and their functions in situ, has completed a successful closure of a €5.3 million funding round. The round was led by existing owners, underscoring their continued commitment and confidence in the company’s vision, progress, and commercial potential. The round also includes a strategic toehold investment from UK-based Meltwind, signaling growing international interest in Navinci’s innovative technology.
The funds will be used to accelerate product development, strengthen operations, and position the company for its next phase of growth. This financing round comes at a pivotal time as Navinci continues to expand its proprietary Naveni® technology, including launching the first ever multiplex in situ proximity ligation assays, and opening a grant program to researchers globally for higher plex, fully customizable assays.
“Our continued investment reflects strong belief in Navinci’s technology and the team’s ability to make a meaningful impact in the life sciences,” said Professor Ulf Landegren, Founder of Navinci and the company’s largest shareholder. “The company stands on a solid scientific foundation, and with this additional support, the company is well-positioned to scale and deliver on its promises in this important research area.”
“At SMA, we back companies with transformative technologies and exceptional teams—Navinci has both. Their progress in spatial proteomics is not only scientifically impressive but also poised for meaningful commercial impact. We are proud to continue supporting their journey and believe they are uniquely positioned to set new standards in the study of protein interactions,” said Maria Tell, COO and Investment Director at Segulah Medical Acceleration (SMA).
Meltwind is led by Dr. Jonathan Milner, a prominent figure in the biotech investment community. With extensive experience in building biotech companies, such as co-founding Abcam, his involvement adds strategic value to Navinci’s investor base, and reinforces the company’s growing international profile.
“Navinci’s approach has the potential to make a significant impact on the understanding of biology by providing deeper insights into protein function and interplay. The company has made strong progress to date and is now well positioned to accelerate its development.” said Dr Jonathan Milner.
For additional information, please contact:
Jenny Sundqvist, Chief Executive Officer
Email: jenny.sundqvist@navinci.se
About Navinci
Navinci is a Swedish biotech company specializing in developing innovative solutions for studying in situ protein expression and interactions. With a focus and a strong legacy in developing in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.
